KMTS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KM

Mkt Cap

$1.62B

Volume

390.24K

Next Earnings

December 10th

Loading chart

KM

KMTSKestra Medical Technologies, Ltd. Common Stock

KMTS

Pay with—

Available Balance0.00

KM

Mkt Cap

$1.62B

Volume

390.24K

Next Earnings

December 10th

Chart Financials Earnings News About Insider Filings

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue EstimatesKestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.Zacks Investment Research · Sep 14, 2026

Kestra Names Daniel Finney Vice President of Research & DevelopmentKestra Medical Technologies announced the appointment of Daniel Finney as Vice President of Research & Development and executive leadership team member. Finney, who has over 20 years of medical device development experience, succeeds Phillip D. Foshee, Jr. and will lead the company's innovation initiatives across the Cardiac Recovery System platform, including AI applications and strategic partnerships.GlobeNewswire Inc. · Sep 10, 2026

Phreesia (PHR) Q2 Earnings and Revenues Lag EstimatesPhreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.Zacks Investment Research · Sep 2, 2026

Kestra Appoints Curtis Kopf as Senior Vice President of Customer ExperienceKestra Medical Technologies announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience in a newly created role. Kopf, who previously led global customer experience at Insulet Corporation and served as Chief Experience Officer at REI, will oversee the patient experience for the ASSURE WCD device. The appointment aligns with Kestra's investments in commercial capabilities and artificial intelligence initiatives to drive growth and improve patient support throughout their cardiac recovery journey.GlobeNewswire Inc. · Aug 26, 2026

Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been named a finalist in the 'Deal of the Year' category for the 2026 GeekWire Awards. The recognition is for the company's successful 2025 initial public offering, which the company states strengthens its ability to invest in growth and accelerate progress toward new standards of care for cardiac patients. Community voting is open through April 16, 2026, with winners to be announced on May 7, 2026.GlobeNewswire Inc. · Mar 25, 2026

Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare ConferenceKestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company focuses on transforming patient outcomes in cardiovascular disease through monitoring and therapeutic intervention technologies.GlobeNewswire Inc. · Dec 30, 2025

Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial ResultsKestra Medical Technologies will report its second quarter fiscal 2026 financial results on December 11, with a conference call scheduled at 4:30 p.m. Eastern Time. The call will be available via webcast on their investor relations website.GlobeNewswire Inc. · Dec 3, 2025

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common SharesKestra Medical Technologies is conducting a public offering of 6,000,000 common shares at $23.00 per share, expecting to raise $138 million. The offering includes an option for underwriters to purchase an additional 900,000 shares.GlobeNewswire Inc. · Dec 3, 2025

Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common SharesKestra Medical Technologies plans to offer 5,500,000 common shares through an underwritten public offering, with potential for an additional 825,000 shares. The proceeds will support sales, marketing, research, development, and general corporate purposes.Benzinga · Dec 1, 2025

Kestra Revenue Jumps 52% in Fiscal Q1Kestra Medical Technologies reported a 52% revenue increase in Q1 FY2026, driven by rising ASSURE wearable defibrillator prescriptions. Despite strong top-line growth, the company experienced widening losses and increased operating expenses.The Motley Fool · Sep 11, 2025

to start trading

KM

KMTSKestra Medical Technologies, Ltd. Common Stock

KMTS

Pay with—

Available Balance0.00

Your PositionYou don't own any KMTS yet.

Related Tickers

Earnings